BD Synapsys Informatics Solution with software versions: 4.20, 4.30, 5.10, 5.20 and 5.30- IVD standalone laboratory software solution providing data management and workflow management functionality across locations where clinical diagnostic activities take place. Catalog Number: 444150
Publicado el 16 de octubre de 2024 · Inicio del retiro: 12 de septiembre de 2024
Resumen
FDA registra el retiro Z-0026-2025 de dispositivos médicos de Clase II, publicado el 16 de octubre de 2024 e iniciado el 12 de septiembre de 2024. Empresa responsable: Becton Dickinson & Co.; Estado: En curso; Cantidad reportada: 162 units; Lote: UDI-DI: 00382904441500 Software versions: 4.20, 4.30, 5.10, 5.20 and 5.30. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Synapsys software versions 4.20, 4.30, 5.10, 5.20, or 5.30 and utilizing the in-line breakpoint feature, an error is occurring where BD Synapsys will incorrectly display breakpoints for organisms that do not have defined breakpoints in CLSI or EUCAST. This occurs when the identified organism is included in the same interpretive group as a species for which there is a specific breakpoint. May result in either a false susceptible or false resistant result. A false susceptible result can cause inadequate or incomplete antibiotic treatment due to the use of an ineffective antibiotic, and a false resistant result may limit access to a preferred antibiotic regimen with possible elongation of therapy
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Becton Dickinson & Co.
- Distribuidor
- Nationwide Foreign: Australia, New Zealand, Singapore, Hong Kong, Taiwan, Japan, Austria, Belgium, Denmark, France, Germany, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, Russia, Saudi Arabia, South Africa, Canada, Mexico, China
- Lote
- UDI-DI: 00382904441500 Software versions: 4.20, 4.30, 5.10, 5.20 and 5.30
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.21 de octubre de 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.21 de octubre de 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic use6 de mayo de 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic use6 de mayo de 2026
- FDABeckman Coulter Dxl 9000 Access Immunoassay Analyzer, REF #C11137. An in vitro diagnostic device used for the16 de octubre de 2024
- FDAAligned Medical Tonsil Tray REF AMS9300A that contains the Cardinal Health Salem Sump PVC tubes. Product16 de octubre de 2024
Preguntas sobre este retiro
¿BD Synapsys Informatics Solution with software versions: 4.20, 4.30, 5.10, 5.20 and 5.30- IVD standalone laboratory software solution providing data management and workflow management functionality across locations where clinical diagnostic activities take place. Catalog Number: 444150 fue retirado del mercado?
Sí. FDA publicó el retiro Z-0026-2025 el 16 de octubre de 2024. Peligro reportado: Synapsys software versions 4.20, 4.30, 5.10, 5.20, or 5.30 and utilizing the in-line breakpoint feature, an error is occurring where BD Synapsys will incorrectly display breakpoints for organisms that do not have defined breakpoints in CLSI or EUCAST. This occurs when the identified organism is included in the same interpretive group as a species for which there is a specific breakpoint. May result in either a false susceptible or false resistant result. A false susceptible result can cause inadequate or incomplete antibiotic treatment due to the use of an ineffective antibiotic, and a false resistant result may limit access to a preferred antibiotic regimen with possible elongation of therapy
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter